(Q46088365)

19 December 2017

title

Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries (English)

1 reference

19 December 2017

1 reference

1 reference

EUROASPIRE Study Group

7

object named as

EUROASPIRE Study Group

0 references

Guy De Backer

3

object named as

Guy De Backer

1 reference

19 December 2017

Kornelia Kotseva

1

1 reference

19 December 2017

David Wood

2

1 reference

19 December 2017

Dirk De Bacquer

4

1 reference

19 December 2017

Kalevi Pyörälä

5

1 reference

19 December 2017

Ulrich Keil

6

1 reference

19 December 2017

EUROASPIRE Study Group

7

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 March 2009

1 reference

19 December 2017

published in

The Lancet

1 reference

19 December 2017

volume

373

1 reference

19 December 2017

page(s)

929-940

1 reference

19 December 2017

issue

9667

1 reference

19 December 2017

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Economic burden of cardiovascular diseases in the enlarged European Union

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Meta-analysis: secondary prevention programs for patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Randomised trials of secondary prevention programmes in coronary heart disease: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Breath carbon monoxide as an indication of smoking habit

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Serum cholesterol during 27 years: assessment of systematic error and affecting factors and their role in interpreting population trends.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Smoking cessation: evidence based recommendations for the healthcare system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Effectiveness of smoking cessation therapies: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Assessment of the white-coat effect.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

beta Blockade after myocardial infarction: systematic review and meta regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

[New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II study].

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Évolution du traitement de sortie après hospitalisation pour syndrome coronaire aigu en France entre 1995 et 2000 : données des études Usik 1995, Prévenir 1 et 2 et Usic 2000

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Secondary prevention through cardiac rehabilitation: position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised con

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960330-5

7 January 2021

10.1016/S0140-6736(09)60330-5

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

19286092

1 reference

19 December 2017